イスラエルで最高の胆嚢癌医師 - トップ12名の医師

ソウラスキー医療センターにおける輝かしいキャリアを持つ、軟部組織および骨腫瘍学の第一人者。

• 胆嚢癌治療プロトコルを専門とする
• サックラー医学部腫瘍学准教授
• 欧州臨床腫瘍学会（ESMO）会員
• 軟部組織・骨腫瘍科部長

ペレス・シャロン医師は、臨床試験に対する患者の態度に関する注目すべき研究を含む、がん治療における革新的な臨床研究を実施しています。

• 幅広い消化器がん外科手術を専門とする
• 腹腔内温熱化学療法（HIPEC）および免疫療法などの先進的治療を提供する
• スーラスキー医療センター（イチロフ）に勤務する

Prof. Nadir Arber is a top gastroenterologist from Israel with over 30 years of experience in the field. He is specialized in the prevention, early diagnostics, and treatment of GI cancers, with education from Hebrew University, Tel Aviv University, and NewYork-Presbyterian Center. He has written over 300 papers on his research and is a member of numerous organizations in the field.

イド・ウルフ博士は、イスラエルのスーラスキー医療センター（イチロフ）の腫瘍内科部門を率いています。豊富な経験を持つ上級腫瘍内科医です。

• 腫瘍内科および内科を専門とする
• 病院において上級の学術的・指導的役職を務める
• ベン＝グリオン大学（ネゲブ）卒業
• 陸軍医療部隊での勤務により追加の経験を積む

Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.

Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.

Dr. Auala Hubert is a board-certified medical oncologist and radiotherapist with 33 years of clinical experience. She works at Hadassah Medical Center and speaks both English and Hebrew. Dr. Hubert leads the Gastrointestinal Cancer Center. She is also a senior physician in the Oncology Department.

She earned her M.D. from Hadassah University Hospital. She holds board certifications in oncology and radiotherapy. Dr. Hubert has passed USMLE Parts I and II. She is a member of the Israel Society of Clinical Oncology, Israel Medical Society, and Israel Cancer Association. Dr. Hubert also serves on several medical and social service committees, where she helps advance cancer care.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.